Sikander Ailawadhi is Associate Professor of Medicine at Mayo Clinic. OpenAlex indexes 705 publications with 7,490 citations (h-index 43); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 1 Sept 2026
Sikander Ailawadhi, MD, is Associate Professor of Medicine at Mayo Clinic, Jacksonville, Florida, Division of Hematology-Oncology. The public record shows 705 publications with 7,490 citations (h-index 43), centered on Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 20 companies.
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: Multiple Myeloma Research and Treatments
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 20 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 61 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 159.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Sponsor: SWOG Cancer Research Network
Industry payments
Updated 1 Sept 2026
20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year20251 payment$15,000openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20255 payments$11,110openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65.2%PD-1 inhibitor38.7%Nivolumab56%Pembrolizumab44%Part B, office-administered≥22 patientsCD38-directed Cytolytic Antibody12.2%Daratumumab100%Part B, office-administered≥17 patientsMetabolism & gastrointestinal
21.5%Other antiemetics17.3%Fosaprepitant100%Part B, office-administered≥32 patientsSerotonin-3 Receptor Antagonist3.4%Palonosetron hcl54%Ondansetron hydrochloride46%Part B, office-administered≥53 patientsMusculoskeletal
5.7%RANK Ligand Inhibitor5.5%Denosumab100%Part B, office-administered≥15 patientsBisphosphonate0.2%Zoledronic acid100%Part B, office-administered≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 1 Sept 2026
185 congress contributions (2005–2026) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
- Cancer Care Beyond Walls (CCBW): A randomized pragmatic trial of home-based versus in-clinic cancer therapy administration.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 1 Sept 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia.
Blood cancer journal
Letter2026 - Management of hematological toxicities after BCMA-directed CAR-T cell therapy.
Blood cancer journal
Article2026 - A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.
Clinical cancer research
Clinical Trial2025 - Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02IAP antagonists induce anti-tumor immunity in multiple myeloma171 citations2016
- 03Therapy for Relapsed Multiple Myeloma140 citations2017
- 04Diagnosis and Management of Waldenström Macroglobulinemia135 citations2017
- 05
Network
Updated 1 Sept 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/sikander-ailawadhi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/sikander-ailawadhi-aa3973168
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Sikander-Ailawadhi-38142944
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/FloridaSocietyofClinicalOncology/photos/dr-sikander-ailawadhi-md-has-been-a-cornerstone-of-flasco-for-many-years-playing/1015809250582167
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/p/DAT4MZYTa34
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Instagram
instagram.com/p/DOWTNHGk7Ah
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MBBS
University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗ - Resident
Medical Microbiology, University College of Medical Sciences, University of Delhi
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗ - Resident
Internal Medicine, SUNY at Buffalo
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗ - Fellow
Medical Oncology, Roswell Park Cancer Institute, SUNY at Buffalo
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗ - Board Certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗ - Board Certified
Medical Oncology (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗
Editorial & leadership roles
journal and society appointments- Peer Review Committee member
Chronic Lymphocytic Leukemia, American Society of Hematology (ASH), 2009 and 2011
2011provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗
- Board Member
Florida Society of Clinical Oncology (FLASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →flasco.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →flasco.org ↗
Secondary affiliations
appointments beyond the home institution- Expert physician
Mayo Clinic Global Health Consulting
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗
Media & interviews
press, podcasts and appearances- OncLive On Air podcast: "Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma" (with Beth Faiman)
discussing IRAKLIA/IZALCO trial data
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic